SCHEMBL27093496

SCHEMBL27093496

Cc1cc(N)ccc1Oc1cc(Cl)n2ncnc2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.36
▸ EGLN2 Q96KS0 9/20 0.36
▸ SCN5A Q14524 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ ERBB2 P04626 2/20 0.32
▸ EGFR P00533 1/20 0.32
▸ NQO2 P16083 1/20 0.32
▸ FECH P22830 1/20 0.32
▸ MYH14 Q7Z406 1/20 0.32
▸ RIPK3 Q9Y572 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ THRB P10828 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29936085 0.87 EGLN2 (0.38) KDM4EEGLN2ERBB2EGFRNQO2
SCHEMBL26697752 0.87 EGLN2 (0.38) KDM4EEGLN2ERBB2EGFRNQO2
SCHEMBL26697782 0.85 EGLN2 (0.36) KDM4EEGLN2ERBB2ALDH1A1LMNA
SCHEMBL29936052 0.80 HTR2A (0.41) HTR2ASLC6A4MEN1KMT2A
SCHEMBL26697649 0.78 ALDH1A1 (0.43) EGLN2MEN1ALDH1A1LMNAMAPT
SCHEMBL29414877 0.77 ERBB2 (0.48) ERBB2EGFRNQO2FECHMYH14
SCHEMBL1192195 0.77 ERBB2 (0.48) ERBB2EGFRNQO2FECHMYH14
SCHEMBL26893267 0.77 EGFR (0.45) ERBB2EGFRNQO2FECHMYH14
SCHEMBL30879388 0.74 DYRK1A (0.42) KDM4ESCN5ASCN9APOLBERBB2
SCHEMBL1192681 0.74 DYRK1A (0.42) KDM4ESCN5ASCN9APOLBERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459485-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-08-09 — — CN disclosed
US-12037346-B2 Amino-substituted heteroaryls for treating cancers with EGFR mutations NUVALENT, INC. (US) 2024-07-16 — — US disclosed
US-12037346-B2 Amino-substituted heteroaryls for treating cancers with EGFR mutations NUVALENT, INC. (US) 2024-07-16 — — US disclosed
EP-4323356-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS Nuvalent, Inc. (US) 2024-02-21 — — EP disclosed
WO-2022221227-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2022-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037346-B2 Amino-substituted heteroaryls for treating cancers with EGFR mutations EGFR, ERBB2, ERBB3 KDM4E 2488/4885EGLN2 1183/4885SCN5A 2456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback